Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study

References

• World Health Organization. WHO coronavirus (COVID-19) dashboard. [cited 2022 Mar 24]. Available from: https://covid19.who.int/region/wpro/country/jp
   Google Scholar
• Yasuhiro F. Pharmaceuticals and medical devices agency. special approval for emergency on first COVID-19 vaccine in Japan 2021. [ cited 2022 March 15]. Available from: https://www.pmda.go.jp/english/about-pmda/0003.pdf
   Google Scholar
• Naito T, Yan Y, and Tabe Y, et al. Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan. Hum Vaccin Immunother. 2022;18(1):1–2.
   PubMed Web of Science ®Google Scholar
• Mori H, Naito T. A rapid increase in the COVID-19 vaccination rate during the Olympic and Paralympic games 2021 in Japan. Hum Vaccin Immunother. 2022;18(1):2010440.
   PubMed Web of Science ®Google Scholar
• Okubo R, Yoshioka T, Ohfuji S, et al. COVID-19 vaccine hesitancy and its associated factors in Japan. Vaccines. 2021;9(6):662.
   PubMed Web of Science ®Google Scholar
• Machida M, Nakamura I, Kojima T, et al. Acceptance of a COVID-19 vaccine in Japan during the COVID-19 pandemic. Vaccines. 2021;9(3):210.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Ozaki A, Bhandari D, et al. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data. J Travel Med. 2021;28(7):taab090.
   PubMed Web of Science ®Google Scholar
• Hirotsu Y, Amemiya K, Sugiura H, et al. Robust antibody responses to the BNT162b2 mRNA vaccine occur within a week after the first dose in previously infected individuals and after the second dose in uninfected individuals. Front Immunol. 2021;12:722766.
   PubMed Web of Science ®Google Scholar
• Mitsunaga T, Ohtaki Y, Seki Y, et al. The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan. PeerJ. 2021;9:e12316.
   PubMed Web of Science ®Google Scholar
• Yoshimura Y, Sasaki H, Miyata N, et al. Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan. J Infect Chemother. 2021;27(12):1713–1715.
   PubMed Web of Science ®Google Scholar
• Kageyama T, Ikeda K, Tanaka S, et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin Microbiol Infect. 2021;27(12):1861.e1–1861.e5.
   Web of Science ®Google Scholar
• Saita M, Yan Y, Ito K, et al. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers in Japan. J Infect Chemother. 2022;28(1):116–119.
   PubMed Web of Science ®Google Scholar
• Otsuka S, Hiraoka K, Suzuoki M, et al. Antibody responses induced by the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in a single community hospital in Japan. J Infect Chemother. 2022;28(4):539–542.
   PubMed Web of Science ®Google Scholar
• Kitagawa H, Kaiki Y, Sugiyama A, et al. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J Infect Chemother. 2022;28(4):576–581.
   PubMed Web of Science ®Google Scholar
• Saciuk Y, Kertes J, Shamir Stein N, et al. Effectiveness of a third dose of BNT162b2 mRNA vaccine. J Infect Dis. 2022;225(1):30–33.
   PubMed Web of Science ®Google Scholar
• Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. 2021;385(15):1393–1400.
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–2100.
   PubMed Web of Science ®Google Scholar
• Moreira ED, Kitchin N, and Xu X, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med. 2022;386(20):1910–1921.
   PubMed Web of Science ®Google Scholar
• Hall VG, Ferreira VH, and Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244–1246.
   PubMed Web of Science ®Google Scholar
• Speer C, Tollner M, Benning L, et al. Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2022;81(4):593–595.
   PubMed Web of Science ®Google Scholar
• Estrada JA, Cheng CY, and Ku SY, et al. Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901. Vaccines. 2022;10(5):655.
   Web of Science ®Google Scholar
• Intapiboon P, Seepathomnarong P, Ongarj J, et al. Immunogenicity and safety of an intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population. Vaccines. 2021;9(12):1375.
   PubMed Web of Science ®Google Scholar
• Munro APS, Janani L, and Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–2276.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Lyke KE, and Deming ME, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022;386(11):1046–1057.
   PubMed Web of Science ®Google Scholar
• Poh XY, Tan CW, Lee IR, et al. Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study, A randomized clinical trial. Clin Infect Dis. 2022. ciac345. DOI:10.1093/cid/ciac345
   PubMed Web of Science ®Google Scholar
• Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences and age. Womens Health. 2021;17:17455065211022262.
   Google Scholar
• Shaw RH, Liu X, Stuart ASV, et al. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Lancet Respir Med. 2022;S2213-2600(22):00163.
   Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Kotaki R, Adachi Y, Moriyama S, et al. SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine. Sci Immunol. 2022;7:eabn8590.
   PubMed Web of Science ®Google Scholar